India Globalization Capital Competitors and Similar CompaniesClear all

India Globalization Capital's competitors and similar companies include Hemogenyx Pharmaceuticals, LifeMine Therapeutics, Sollis Therapeutics and Cour Pharmaceuticals Development.
India Globalization Capital
India Globalization Capital
India Globalization Capital develops intellectual property for the treatment of life altering or life threatening conditions, through its research on phytocannabinoid-based therapies, in the United States.
Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals, formerly Silver Falcon, is a pre-clinical stage biopharmaceutical company.
LifeMine Therapeutics
LifeMine Therapeutics
LifeMine Therapeutics is a pharmaceutical company that develops fungi-based therapies.
Sollis Therapeutics
Sollis Therapeutics
Sollis Therapeutics is a pharmaceutical company developing non-steroid, non-opioid solutions to treat pain conditions.
Cour Pharmaceuticals Development
Cour Pharmaceuticals Development
Cour Pharmaceuticals Development is a company developing treatments and cures for immune-mediated diseases.
Founding Date
Founding Date
2005
Founding Date
2013
Founding Date
2017
Founding Date
2017
Founding Date
2012
Type
Type
Public
Type
Public
Type
Private
Type
Private
Type
Private
Tags
Locations
Locations
Bethesda, US HQ
Locations
London, GB HQ
Locations
Cambridge, US HQ
Basel, CH
Gloucester, US
Locations
Columbus, US HQ
Hilliard, US
Locations
Northbrook, US HQ
Employees
Employees
50150% increase
Employees
16
Employees
6811% decrease
Employees
283% decrease
Employees
771% decrease
Valuation ($)
Valuation ($)
30 m
Valuation ($)
23.1 m
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A

Financial

Revenue (est.)
Revenue (est.)
$869k (FY, 2025)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Cost of goods
Cost of goods
$572k (FY, 2025)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$297k (FY, 2025)
Gross profit
£7k (FY, 2025)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($4.1m) (FY, 2025)
Net income
(£9.8m) (FY, 2025)
Net income
N/A
Net income
N/A
Net income
N/A

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 55m (over 8 years ago)
Latest funding round
$ 50m (about 8 years ago)
Latest funding round
$ 17k (about 13 years ago)
Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 55m
Total funding raised
$ 50m
Total funding raised
$ 17k
For sources of this data, please see the company profile

View Company Profiles

Hemogenyx Pharmaceuticals
HQ
London, GB
Employees
16

Hemogenyx Pharmaceuticals, formerly Silver Falcon, is a pre-clinical stage biopharmaceutical company.

View company
LifeMine Therapeutics
HQ
Cambridge, US
Employees
68↓ 11% decrease

LifeMine Therapeutics is a pharmaceutical company that develops fungi-based therapies.

View company
Sollis Therapeutics
HQ
Columbus, US
Employees
28↓ 3% decrease

Sollis Therapeutics is a pharmaceutical company developing non-steroid, non-opioid solutions to treat pain conditions.

View company
Cour Pharmaceuticals Development
HQ
Northbrook, US
Employees
77↓ 1% decrease

Cour Pharmaceuticals Development is a company developing treatments and cures for immune-mediated diseases.

View company